Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties

被引:11
|
作者
Ma, Lichun [1 ]
Wang, Debby D. [1 ]
Huang, Yiqing [2 ]
Wong, Maria P. [3 ]
Lee, Victor H. F. [3 ]
Yan, Hong [1 ]
机构
[1] City Univ Hong Kong, Dept Elect Engn, Kowloon, Hong Kong, Peoples R China
[2] Soochow Univ, Sch Comp Sci & Technol, Suzhou, Peoples R China
[3] Univ Hong Kong, Li Ka Sing Fac Med, Pokfulam, Hong Kong, Peoples R China
关键词
Drug resistance; EGFR mutation; Lung cancer; Alpha shape; Solid angle; Protein surface geometric properties; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; GEFITINIB; PREDICTION; DESIGN; ASSOCIATION; TUMORS;
D O I
10.1016/j.compbiomed.2014.06.016
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Epidermal growth factor receptor (EGFR) mutation-induced drug resistance leads to a limited efficacy of tyrosine kinase inhibitors during lung cancer treatments. In this study, we explore the correlations between the local surface geometric properties of EGFR mutants and the progression-free survival (PFS). The geometric properties include local surface changes (four types) of the EGFR mutants compared with the wild-type EGER, and the convex degrees of these local surfaces. Our analysis results show that the Spearman's rank correlation coefficients between the PFS and three types of local surface properties are all greater than 0.6 with small P-values, implying a high significance. Moreover, the number of atoms with solid angles in the ranges of [0.71,1], [0.61,1] or [10.5, 1], indicating the convex degree of a local EGFR surface, also shows a strong correlation with the PFS. Overall, these characteristics can be efficiently applied to the prediction of drug resistance in lung cancer treatments, and easily extended to other cancer treatments. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:293 / 300
页数:8
相关论文
共 50 条
  • [1] Personalized prediction of EGFR mutation-induced drug resistance in lung cancer
    Wang, Debby D.
    Zhou, Weiqiang
    Yan, Hong
    Wong, Maria
    Lee, Victor
    SCIENTIFIC REPORTS, 2013, 3
  • [2] Personalized prediction of EGFR mutation-induced drug resistance in lung cancer
    Debby D. Wang
    Weiqiang Zhou
    Hong Yan
    Maria Wong
    Victor Lee
    Scientific Reports, 3
  • [3] Computational Evaluation of EGFR Dynamic Characteristics in Mutation-induced Drug Resistance Prediction
    Duan, Baobin
    Zou, Bin
    Wang, Debby D.
    Yan, Hong
    Han, Lixin
    2015 IEEE INTERNATIONAL CONFERENCE ON SYSTEMS, MAN, AND CYBERNETICS (SMC 2015): BIG DATA ANALYTICS FOR HUMAN-CENTRIC SYSTEMS, 2015, : 2299 - 2304
  • [4] A mutation-induced drug resistance database (MdrDB)
    Ziyi Yang
    Zhaofeng Ye
    Jiezhong Qiu
    Rongjun Feng
    Danyu Li
    Changyu Hsieh
    Jonathan Allcock
    Shengyu Zhang
    Communications Chemistry, 6
  • [5] A mutation-induced drug resistance database (MdrDB)
    Yang, Ziyi
    Ye, Zhaofeng
    Qiu, Jiezhong
    Feng, Rongjun
    Li, Danyu
    Hsieh, Changyu
    Allcock, Jonathan
    Zhang, Shengyu
    COMMUNICATIONS CHEMISTRY, 2023, 6 (01)
  • [6] Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics
    Ma, Lichun
    Zou, Bin
    Yan, Hong
    PROTEOME SCIENCE, 2016, 14
  • [7] Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics
    Lichun Ma
    Bin Zou
    Hong Yan
    Proteome Science, 14
  • [8] Bioinformatics toolbox for exploring target mutation-induced drug resistance
    Huang, Yuan-Qin
    Sun, Ping
    Chen, Yi
    Liu, Huan-Xiang
    Hao, Ge-Fei
    Song, Bao-An
    BRIEFINGS IN BIOINFORMATICS, 2023, 24 (02)
  • [9] Drug Resistance to EGFR Inhibitors in Lung Cancer
    Tetsu, Osamu
    Hangauer, Matthew J.
    Phuchareon, Janyaporn
    Eisele, David W.
    McCormick, Frank
    CHEMOTHERAPY, 2015, 61 (05) : 223 - 235
  • [10] Emerging treatment for advanced lung cancer with EGFR mutation
    Inal, Cengiz
    Yilmaz, Emrullah
    Piperdi, Bilal
    Perez-Soler, Roman
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2015, 20 (04) : 597 - 612